Stay updated on Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial

Sign up to get notified when there's something new on the Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The clinical trial record for tabelecleucel plus pembrolizumab in EBV-associated nasopharyngeal carcinoma is now displayed, including its study design, eligibility, outcomes, and posted results. It reports that the study was terminated after Phase 1B and that Phase 2 was not conducted.
    Difference
    73%
    Check dated 2026-11-09T14:39:08.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The footer now identifies the site as revision v3.8.0 instead of v3.7.2, while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-11-02T16:23:43.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    A site-wide notice announces a terminology change from “Artificial Intelligence” to “Super Intelligence” and links to transition updates and FAQs. The study page still displays a 403 error.
    Difference
    1%
    Check dated 2026-10-26T15:37:08.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.1 to v3.7.2 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-19T16:29:11.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1, while the study record remains unavailable behind a 403 error.
    Difference
    0.2%
    Check dated 2026-10-12T16:32:40.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error page, with a 403 title and Forbidden message shown in the HTML, indicating access restrictions rather than study content. The site layout remains visible, but substantive content is not accessible.
    Difference
    21%
    Check dated 2026-09-21T20:24:52.000Z thumbnail image

Stay in the know with updates to Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial page.